TScan Q2 net loss $15.1M; cash $125.6M funds into 2024; TSC-101 IND cleared

TScan Therapeutics, Inc.

2022-Q2 EPS reported -$1.30 revenue$7,077,000

Net loss $15.1M vs $10.7M in prior-year quarter; revenue $4.1M (up from $2.8M) on Novartis collaboration.
Cash and equivalents $125.6M (plus $5M restricted); runway into 2024.
FDA cleared IND for TSC-101 (HA-2) for HCT relapse prevention; Phase 1 umbrella trial now enrolling.
Debora Barton, M.D., appointed Chief Medical Officer; brings cell therapy and oncology R&D experience.
Plans to file INDs for solid-tumor candidates TSC-200-A2 (HPV) and TSC-204-C7 (MAGE-A1) by year-end 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.